Cargando…

Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia

BACKGROUND AND OBJECTIVE: Dopamine plays an important role in the disease pathology of Parkinson’s disease and schizophrenia. These two neuropsychiatric disorders represent disease end points of the dopaminergic spectrum where Parkinson’s disease represents dopamine deficit and schizophrenia represe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Ashish Kumar, Pokhriyal, Ruchika, Das, Uddipan, Khan, Mohd Imran, Ratna Kumar, Domada, Gupta, Rishab, Chadda, Rakesh Kumar, Ramachandran, Rashmi, Goyal, Vinay, Tripathi, Manjari, Hariprasad, Gururao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650621/
https://www.ncbi.nlm.nih.gov/pubmed/31410011
http://dx.doi.org/10.2147/NDT.S205550
_version_ 1783438168694980608
author Gupta, Ashish Kumar
Pokhriyal, Ruchika
Das, Uddipan
Khan, Mohd Imran
Ratna Kumar, Domada
Gupta, Rishab
Chadda, Rakesh Kumar
Ramachandran, Rashmi
Goyal, Vinay
Tripathi, Manjari
Hariprasad, Gururao
author_facet Gupta, Ashish Kumar
Pokhriyal, Ruchika
Das, Uddipan
Khan, Mohd Imran
Ratna Kumar, Domada
Gupta, Rishab
Chadda, Rakesh Kumar
Ramachandran, Rashmi
Goyal, Vinay
Tripathi, Manjari
Hariprasad, Gururao
author_sort Gupta, Ashish Kumar
collection PubMed
description BACKGROUND AND OBJECTIVE: Dopamine plays an important role in the disease pathology of Parkinson’s disease and schizophrenia. These two neuropsychiatric disorders represent disease end points of the dopaminergic spectrum where Parkinson’s disease represents dopamine deficit and schizophrenia represents dopamine hyperactivity in the mid-brain. Therefore, current treatment strategies aim to restore normal dopamine levels. However, during treatment patients develop adverse effects due to overshooting of physiological levels of dopamine leading to psychosis in Parkinson’s disease, and extrapyramidal symptoms in schizophrenia. Absence of any laboratory tests hampers modulation of pharmacotherapy. Apolipoprotein E and α-synuclein have an important role in the neuropathology of these two diseases. The objective of this study was to evaluate cerebrospinal fluid (CSF) concentrations of apolipoprotein E and α-synuclein in patients with these two diseases so that they may serve as biomarkers to monitor therapy in Parkinson’s disease and schizophrenia. METHODS: Drug-naïve Parkinson’s disease patients and Parkinson’s disease patients treated with dopaminergic therapy, neurological controls, schizophrenic patients treated with antidopaminergic therapy, and drug-naïve schizophrenic patients were recruited for the study and CSF was collected. Enzyme-linked immunosorbent assays were carried out to estimate the concentrations of apolipoprotein E and α-synuclein. Pathway analysis was done to establish a possible role of these two proteins in various pathways in these two dopamine dictated diseases. RESULTS: Apolipoprotein E and α-synuclein CSF concentrations have an inverse correlation along the entire dopaminergic clinical spectrum. Pathway analysis convincingly establishes a plausible hypothesis for their co-regulation in the pathogenesis of Parkinson’s disease and schizophrenia. Each protein by itself or as a combination has encouraging sensitivity and specificity values of more than 55%. CONCLUSION: The dynamic variation of these two proteins along the spectrum is ideal for them to be pursued as pharmacotherapeutic biomarkers in CSF to monitor pharmacological efficacy in Parkinson’s disease and schizophrenia.
format Online
Article
Text
id pubmed-6650621
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66506212019-08-13 Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia Gupta, Ashish Kumar Pokhriyal, Ruchika Das, Uddipan Khan, Mohd Imran Ratna Kumar, Domada Gupta, Rishab Chadda, Rakesh Kumar Ramachandran, Rashmi Goyal, Vinay Tripathi, Manjari Hariprasad, Gururao Neuropsychiatr Dis Treat Original Research BACKGROUND AND OBJECTIVE: Dopamine plays an important role in the disease pathology of Parkinson’s disease and schizophrenia. These two neuropsychiatric disorders represent disease end points of the dopaminergic spectrum where Parkinson’s disease represents dopamine deficit and schizophrenia represents dopamine hyperactivity in the mid-brain. Therefore, current treatment strategies aim to restore normal dopamine levels. However, during treatment patients develop adverse effects due to overshooting of physiological levels of dopamine leading to psychosis in Parkinson’s disease, and extrapyramidal symptoms in schizophrenia. Absence of any laboratory tests hampers modulation of pharmacotherapy. Apolipoprotein E and α-synuclein have an important role in the neuropathology of these two diseases. The objective of this study was to evaluate cerebrospinal fluid (CSF) concentrations of apolipoprotein E and α-synuclein in patients with these two diseases so that they may serve as biomarkers to monitor therapy in Parkinson’s disease and schizophrenia. METHODS: Drug-naïve Parkinson’s disease patients and Parkinson’s disease patients treated with dopaminergic therapy, neurological controls, schizophrenic patients treated with antidopaminergic therapy, and drug-naïve schizophrenic patients were recruited for the study and CSF was collected. Enzyme-linked immunosorbent assays were carried out to estimate the concentrations of apolipoprotein E and α-synuclein. Pathway analysis was done to establish a possible role of these two proteins in various pathways in these two dopamine dictated diseases. RESULTS: Apolipoprotein E and α-synuclein CSF concentrations have an inverse correlation along the entire dopaminergic clinical spectrum. Pathway analysis convincingly establishes a plausible hypothesis for their co-regulation in the pathogenesis of Parkinson’s disease and schizophrenia. Each protein by itself or as a combination has encouraging sensitivity and specificity values of more than 55%. CONCLUSION: The dynamic variation of these two proteins along the spectrum is ideal for them to be pursued as pharmacotherapeutic biomarkers in CSF to monitor pharmacological efficacy in Parkinson’s disease and schizophrenia. Dove 2019-07-19 /pmc/articles/PMC6650621/ /pubmed/31410011 http://dx.doi.org/10.2147/NDT.S205550 Text en © 2019 Gupta et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Gupta, Ashish Kumar
Pokhriyal, Ruchika
Das, Uddipan
Khan, Mohd Imran
Ratna Kumar, Domada
Gupta, Rishab
Chadda, Rakesh Kumar
Ramachandran, Rashmi
Goyal, Vinay
Tripathi, Manjari
Hariprasad, Gururao
Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
title Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
title_full Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
title_fullStr Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
title_full_unstemmed Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
title_short Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia
title_sort evaluation of α-synuclein and apolipoprotein e as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of parkinson’s disease and schizophrenia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650621/
https://www.ncbi.nlm.nih.gov/pubmed/31410011
http://dx.doi.org/10.2147/NDT.S205550
work_keys_str_mv AT guptaashishkumar evaluationofasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonsdiseaseandschizophrenia
AT pokhriyalruchika evaluationofasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonsdiseaseandschizophrenia
AT dasuddipan evaluationofasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonsdiseaseandschizophrenia
AT khanmohdimran evaluationofasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonsdiseaseandschizophrenia
AT ratnakumardomada evaluationofasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonsdiseaseandschizophrenia
AT guptarishab evaluationofasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonsdiseaseandschizophrenia
AT chaddarakeshkumar evaluationofasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonsdiseaseandschizophrenia
AT ramachandranrashmi evaluationofasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonsdiseaseandschizophrenia
AT goyalvinay evaluationofasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonsdiseaseandschizophrenia
AT tripathimanjari evaluationofasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonsdiseaseandschizophrenia
AT hariprasadgururao evaluationofasynucleinandapolipoproteineaspotentialbiomarkersincerebrospinalfluidtomonitorpharmacotherapeuticefficacyindopaminedictateddiseasestatesofparkinsonsdiseaseandschizophrenia